SCHEDULE: Domicilium Capital Discloses 4.9% Stake in Eloxx Pharma

Investment firm Domicilium Capital Partners and affiliates report a 4.9% beneficial ownership stake in Eloxx Pharmaceuticals, Inc.

Summary

• Domicilium Capital Partners LLC and Daniel Simon report beneficial ownership of 23,478 shares of Eloxx Pharmaceuticals, Inc. common stock.
• The reported stake represents 4.9% of the company's outstanding common stock.
• The filing notes that the share count reflects an 11-for-1 reverse stock split that became effective on May 29, 2026.
• The securities are held on behalf of advisory clients of Domicilium Capital Partners LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure indicating standard institutional investment activity without activist implications.

Positives

• The reporting persons explicitly state the shares were not acquired for the purpose of changing or influencing the control of the issuer.

Negatives

• The reporting entities hold less than 5% of the company's outstanding shares, keeping them below the standard threshold for significant activist disclosure.

Risks

• The investment is subject to the volatility of the pharmaceutical sector and the specific clinical and regulatory risks associated with Eloxx Pharmaceuticals' pipeline.

Future Outlook

The reporting persons have certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G are standard regulatory disclosures for investment firms managing client assets and do not necessarily signal a strategic shift or activist intent.

Comparison to Industry Standards

• The filing follows standard SEC reporting requirements for institutional investors under Section 13(d) and 13(g) of the Securities Exchange Act.
• The disclosure of a sub-5% stake is consistent with passive investment management practices.

Stakeholder Impact

• Shareholders should note the presence of this institutional investor, though the passive nature of the holding suggests no immediate change in corporate strategy.

Next Steps

• The reporting persons will continue to monitor their position in Eloxx Pharmaceuticals in accordance with their investment advisory mandates.

Key Dates

Keywords

Eloxx Pharmaceuticals, Schedule 13G, Beneficial Ownership, Domicilium Capital, Reverse Stock Split, Institutional Investor